Lumateperonum
 |
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
| Cognitores | |
|---|---|
| ChemSpider | 7997690 |
| PubChem | 9821941 |
| DrugBank | DB06077 |
| Natura chemica | |
| |
| Formula summarum | C 24H 28FN 3O |
| Massa molaris | 393.506 g/mol |
| Ad usum therapeuticum | |
| Applicatio | per os |
| MedlinePlus | a620014 (Anglice) |
Lumateperonum (antea: ITI-007) est antipsychotica atypicum et medicamentum ad therapiam schizophreniarum praescriptum[1]. Virtutes suae ad systemata et serotonergicum et dopaminergicum et glutamatergicum spectant[2].
Natura Lumateperoni[recensere | fontem recensere]
Natura chemica[recensere | fontem recensere]
Structura chemica Lumateperoni est 1-(4-Fluorophenylo)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyridino[3',4':4,5]pyrrolo[1,2,3-de]quinoxalino-8(7H)-yl)-1-butanonum. Massa molaris est 393.506 g/mol.
Pharmacodynamica[recensere | fontem recensere]
| Receptorium | Lumateperoni affinitas ligandi, Ki (nM)[3] |
Actio |
|---|---|---|
| dopamini D1 | 4.1 | |
| dopamini D2 | 3.2 | prae- et postsynapticum |
| serotonini 5-HT2A | 0.54 | |
| SERT | 3.3 |
Lumateperonum receptoria D2 postsynaptica inhibet, at etiam agonista praesynapticarum receptoriorum D2 agit. Praeterea inhibitio receptoriorum serotonergicorum 5HT2A descripta est.
Nexus interni
Notae[recensere | fontem recensere]
- ↑ Vyas P., Hwang B. J., Brašić J. R. (Feb 2020). An evaluation of lumateperone tosylate for the treatment of schizophrenia. 21. pp. 139-45
- ↑ Kumar B., Kuhad A., Kuhad A. (Dec 2018). "Lumateperone: a new treatment approach for neuropsychiatric disorders". Drugs of today 54 (12): 713-9
- ↑ https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php